Biocon Biologics launches product for autoimmune diseases in Australia

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating autoimmune diseases like rheumatoid arthritis. Marketed through Generic Health, Nepexto aims to broaden patient access in the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZeVsntL
via IFTTT